Bio-Path Holdings Inc (BPTH) concluded trading on Thursday at a closing price of $1.49, with 113.23 million shares of worth about $168.71 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -29.38% during that period and on December 19, 2024 the price saw a gain of about 122.72%. Currently the company’s common shares owned by public are about 4.31M shares, out of which, 4.31M shares are available for trading.
Stock saw a price change of 112.71% in past 5 days and over the past one month there was a price change of 86.48%. Year-to-date (YTD), BPTH shares are showing a performance of -83.91% which decreased to -83.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.59 but also hit the highest price of $12.00 during that period. The average intraday trading volume for Bio-Path Holdings Inc shares is 1.18 million. The stock is currently trading 97.25% above its 20-day simple moving average (SMA20), while that difference is up 66.50% for SMA50 and it goes to -23.37% lower than SMA200.
Bio-Path Holdings Inc (NASDAQ: BPTH) currently have 4.31M outstanding shares and institutions hold larger chunk of about 1.37% of that.
The stock has a current market capitalization of $6.41M and its 3Y-monthly beta is at 0.23. It has posted earnings per share of -$12.20 in the same period. It has Quick Ratio of 0.86. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BPTH, volatility over the week remained 39.46% while standing at 20.76% over the month.
Stock’s fiscal year EPS is expected to rise by 90.57% while it is estimated to increase by 51.10% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on March 11, 2021 offering a Buy rating for the stock and assigned a target price of $13 to it. Coverage by H.C. Wainwright stated Bio-Path Holdings Inc (BPTH) stock as a Buy in their note to investors on November 13, 2017, suggesting a price target of $1.50 for the stock. On August 10, 2016, Maxim Group Reiterated their recommendations, while on April 18, 2016, Rodman & Renshaw Initiated their ratings for the stock with a price target of $5. Stock get a Buy rating from Maxim Group on June 02, 2014.
